Just as early preclinical data on CD38/CD3xCD28 trispecific antibody therapy are emerging, along with ongoing CAR-T therapy trials targeting CD5, CD7, CD30, CD70 or TRBC1 that are highly anticipated to advance the immunotherapy landscape in PTCL, we are already witnessing promising results from early trials [171]. This evidence concerns the gene TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma.